FDA (Drugs) recall action 70452

Attix Pharmaceuticals recalled 470 products on 2015-04-29

The FDA (Drugs) publishes a recall like this one as 470 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 470 pages.

Products: 470
Announced: 2015-04-29
Critical: 0
Units: 2,350

Why these products were recalled

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Stability Data Does Not Support Expiry: All lots of all products repackaged and distributed between 01/05/12 through 02/12/15 are being recalled because they were repackaged without data to support the printed expiry date.

The agency’s own wording, quoted from the enforcement report.

The unit total adds up the quantities the agency stated for each product. Where a product record gave no figure, or gave a weight rather than a count, it contributes nothing — so the real total is at least this, never less.

376–400 of 470

SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Albendazole Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Albendazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Albendazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Streptomycin Sulfate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Streptomycin Sulfate API because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.
Product
Streptomycin Sulfate or Sulphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Hydroxyprogesterone Caproate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hydroxyprogesterone Caproate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Hydroxyprogesterone Caproate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Amlodipine Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Amlodipine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Amlodipine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Methocarbamol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling methocarbamol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Methocarbamol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Hydroxyurea Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hydroxyurea active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydroxyurea active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Ketoconazole API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Ketoconazole active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Ketoconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Levosulpiride API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Levosulpiride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Levosulpiride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Doxapram HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Doxapram HCI Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Doxapram HCI Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Aldosterone API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Aldosterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Aldosterone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Benazepril HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Benazepril HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Benazepril HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Clomiphene Citrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Clomiphene Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Clomiphene Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Miconazole Nitrate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Miconazole Nitrate active ingredient due to potential penicillin cross-contamination during repackaging.
Product
Miconazole Nitrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Cinacalcet HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Cinacalcet HCI active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Cinacalcet HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Cyclosporine A Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cyclosporine A active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cyclosporine A active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Nitrofurantoin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Nitrofurantoin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.
Product
Nitrofurantoin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Chlorobutanol Hemihydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Chlorobutanol Hemihydrate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Chlorobutanol Hemihydrate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Olsalazine Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Olsalazine Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Olsalazine Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Podophyllum Resin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Podophyllum Resin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Podophyllum Resin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Sirlolimus API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Sirlolimus active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Sirlolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Oxcarbazepine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling oxcarbazepine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Oxcarbazepine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Ranitidine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Ranitidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Ranitidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Idoxuridine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Idoxuridine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Idoxuridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Ribavirin Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Ribavirin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Ribavirin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Bromhexine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Bromhexine HCl active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Bromhexine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states